Supplied as a white to off-white, free-flowing powder, croscarmellose sodium is a cross-linked, partly O-carboxymethylated cellulose with CAS 74811-65-7. The material is not an active pharmaceutical ingredient in the therapeutic sense; the product designation “API” is used here as a pharmacopoeial grade identifier for formulation use. Compendial acceptance criteria follow USP-NF and Ph. Eur. monograph parameters: pH of a 1% dispersion 5.0–7.0, loss on drying ≤10.0%, degree of substitution 0.60–0.85, settling volume 10.0–30.0 mL, and water-soluble substances ≤10.0%. These limits define the degree of crosslinking and carboxymethyl substitution that control swelling, wicking, and gel formation. As a superdisintegrant, it is incorporated at 0.5–5.0 wt% in tablet and capsule formulations, with optimum ranges typically 2–4 wt% depending on compression force and granulation route. The powder is practically insoluble in water but swells rapidly; this property is the basis for disintegration performance.

How Does Cross-Linked Carboxymethylcellulose Generate Disintegration Force Under Tablet Compression?

Disintegrant action involves two simultaneous mechanisms: capillary wicking into the tablet pore network and swelling of cross-linked polymer domains after contact with aqueous media. Wicking rate follows porous-media transport kinetics in which penetration distance increases with the square root of time, controlled by pore radius, contact angle, and fluid viscosity. Lower bulk-density grades with irregular particle morphology generate a broader pore network but may reduce tablet tensile strength. Swelling is controlled by the degree of substitution and the density of cross-link junctions. The compendial settling volume of 10.0–30.0 mL is a quality-control proxy for swelling capacity. In tablet cores compressed on rotary presses between 8 kN and 25 kN, the disintegrant must overcome interparticulate bonding and hydraulic pressure from dissolution media. USP <701> basket-rack apparatus with discs at 37±2 °C is used to evaluate disintegration time in purified water or simulated gastric fluid. Tablets containing croscarmellose at 2–4 wt% typically achieve disintegration times below 15 min for immediate-release formulations, although the acceptance criterion is product-specific. USP <711> Apparatus 2 at 50 rpm is used separately to verify that release remains within product-specific criteria. The swelling stress generated inside a tablet matrix is constrained by tablet porosity and bond strength; if swelling occurs before the wicking front has fully penetrated the core, surface gel formation can seal off remaining pores and prolong disintegration.

Compendial Monograph Limits and Certificate-of-Analysis Profiles

Specification testing is divided between universal monograph limits and supplier-specific particle-size and bulk-density controls. The following parameters are taken from USP-NF and Ph. Eur. monographs for croscarmellose sodium; actual certificates of analysis may include additional controls for particle size, residual solvents, and microbial limits.

Particle-size differentiation is supplier-controlled rather than compendial. Direct-compression grades are typically characterized by laser diffraction according to ISO 13320:2020 and can carry d50 values between 40 µm and 100 µm; wet-granulation grades may be selected for low fines to reduce dusting. The certificate of analysis should be checked for bulk density by USP <616> and powder flow; bulk density below 0.45 g/mL may require forced feed on high-speed rotary presses. Because the monograph allows a degree of substitution range of 0.60–0.85, lot-to-lot swelling capacity can vary within this range and should be evaluated during process validation. Residual water and sodium chloride content are also relevant to compatibility: sodium chloride and sodium glycolate at ≤0.5% affect ionic strength in aqueous granulation and can alter swelling rate. Microbial quality is controlled to non-sterile oral excipient limits, with total aerobic microbial count ≤10³ CFU/g and total combined yeasts and moulds ≤10² CFU/g by Ph. Eur. 2.6.12 and 2.6.13.

When Particle-Size Selection Shifts Disintegration Time in Wet Granulation

Addition mode is a critical process variable. Intragranular addition at 1–3 wt% places croscarmellose within the granule matrix; extragranular addition at 1–3 wt% provides rapid separation between granules. In high-shear granulators with impeller tip speeds of 5–15 m/s, intragranular croscarmellose can be sheared into fine particles that occlude pores and reduce effective swelling. Wet massing time and water quantity must be controlled because croscarmellose swells during granulation. Over-granulation produces dense granules with tablet crushing strength above 2.5 MPa and disintegration times exceeding 30 min in USP <701>. The risk is mitigated by splitting the dose: 50% intragranular and 50% extragranular in a twin-shell blender after lubrication. Blending time after extragranular addition should be limited to 10–15 min at 15 rpm to avoid demixing. In fluid-bed granulation, inlet air temperature 50–70 °C and final moisture set point 2–4% prevent premature swelling during spraying; granule size D50 between 100 µm and 300 µm is typically targeted for subsequent tableting.

Evaluating Lubricant Sensitivity in High-Shear and Twin-Shell Blending

Magnesium stearate at 0.5–1.0 wt% can coat croscarmellose particles and retard water uptake. In twin-shell blenders with rotation at 15–30 rpm, croscarmellose should be added before lubricant or separated by a pre-blend step. A high-shear mixer with chopper speed 1000–3000 rpm can generate frictional heat and moisture migration; lot-to-lot moisture content above 6.0% increases particle agglomeration and reduces flow through the tablet press feed frame. The blending sequence should be fixed during validation: active substance and fillers, then croscarmellose, then magnesium stearate. Lubrication time greater than 5 min under high shear is associated with delayed disintegration due to hydrophobic film formation. Compression force should be increased gradually until friability is ≤1.0% by USP <1216>; excessive force above the region where hardness plateaus can increase disintegration times. Ejection force should be monitored during batch compression; significant ejection force drift can indicate lubricant overmixing or moisture uptake in the feed frame.

The product line nomenclature includes oral and injectable routes, but croscarmellose sodium compendial grade is not listed as an inactive ingredient for injection in the United States FDA Inactive Ingredient Database. Its insoluble, swelling particle network makes it unsuitable for parenteral formulations, where particulate load and vascular occlusion risk require soluble or parenteral-grade colloidal vehicles. For oral suspension use, croscarmellose acts as a suspending and disintegrating aid; the settling volume test of 10.0–30.0 mL remains a quality-control parameter. In dispersible tablets and oral lyophilisates, the same grade may be used at 2–5 wt% to ensure rapid disintegration in water before swallowing. No injectable formulation should incorporate this material without specific toxicological and compendial support. Published data for injectable configurations are limited, and the absence of a parenteral listing in the FDA inactive ingredient database is a regulatory limitation.

Croscarmellose Swells More Than Crospovidone but Is Less Prone to Gel Blocking Than Starch Glycolate

Formulators select among superdisintegrants based on swelling, wicking, and ionic-strength sensitivity. Croscarmellose sodium combines high swelling with moderate wicking; crospovidone is predominantly a wicking agent and does not gel; sodium starch glycolate swells rapidly but can form a viscous gel layer that slows media penetration at high concentrations. In direct compression of poorly soluble actives, croscarmellose at 2–4 wt% often provides faster disintegration than pregelatinized starch at 5–10 wt%. Tablets containing croscarmellose may retain hardness better than those containing high wicking agents because croscarmellose does not rely solely on capillary channels. Ionic strength of the dissolution medium influences carboxylate swelling; media with sodium chloride above 0.1 M may reduce swelling capacity through charge shielding. This is less pronounced for crospovidone, which has no ionizable group. In high-dose acidic actives, croscarmellose may be preferred over sodium starch glycolate because the latter can create a viscous gel layer at local pH below 3.

Which Processing Boundaries Require Pre-Drying and Moisture Control?

Croscarmellose sodium is hygroscopic. Bulk material exposed to relative humidity above 60% can gain more than 2% moisture within 24 h; pre-drying in a tray dryer at 40–50 °C for 2–4 h is required before dry blending if the moisture content exceeds the certificate-of-analysis value. Overdrying below 2% may generate static and reduce flow. The material is incompatible with strongly acidic media below pH 4 and with high concentrations of multivalent cations, which can complex with carboxylate groups and depress swelling. Do not combine with amine-based film coatings or cationic polymers in the same granulation without compatibility testing; cationic charge can neutralize the anionic carboxymethyl groups. Equipment cleanout after croscarmellose use requires dry vacuum or low-humidity compressed air because water-washed surfaces leave a slick residue film. Storage should be in closed containers at 15–25 °C and ≤60% relative humidity; opened drums should be re-closed immediately after weighing to prevent moisture uptake.